70622-91-2

Basic information

• Product Name: 1-phenyl-3-(3-phenylpropyl)urea
• Synonyms: urea, N-phenyl-N'-(3-phenylpropyl)-
• CAS NO: 70622-91-2
• Molecular Formula: C₁₆H₁₈N₂O
• Molecular Weight: 254.3269
• Mol File: 70622-91-2.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 393.9°C at 760 mmHg
• Flash Point: 141.4°C
• Density: 1.13g/cm³
• Vapor Pressure: 2.06E-06mmHg at 25°C
• Refractive Index: 1.608
• CAS DataBase Reference: 1-phenyl-3-(3-phenylpropyl)urea(CAS DataBase Reference)
• NIST Chemistry Reference: 1-phenyl-3-(3-phenylpropyl)urea(70622-91-2)
• EPA Substance Registry System: 1-phenyl-3-(3-phenylpropyl)urea(70622-91-2)

Safety Data

• Hazardous Substances Data: 70622-91-2(Hazardous Substances Data)

Usage

Chemical class

Urea compounds

Usage

Precursor in the synthesis of other organic compounds

Structural components

Phenyl group, 3-(3-phenylpropyl) group, urea functional group

Chemical properties

Diverse due to the presence of different functional groups

Applications

Building block in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds

Potential uses

Medicinal chemistry due to structural characteristics

Upstream product

• 68664-23-3 3-phenylpropylisocyanate 
• 62-53-3 aniline 
• 637-59-2 1-Bromo-3-phenylpropane 
• 27126-20-1 (3-azidopropyl)benzene 
• 201230-82-2 carbon monoxide 
• 103-71-9 phenyl isocyanate 
• 501-52-0 3-Phenylpropionic acid 
• 2038-57-5 3-Phenylpropan-1-amine 

Relevant articles and documents

Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure

A series of flexible urea derivatives have been synthesized and demonstrated as selective cardiac myosin ATPase activator. Among them 1-phenethyl-3-(3-phenylpropyl)urea (1, cardiac myosin ATPase activation at 10?μM?=?51.1%; FS?=?18.90; EF?=?12.15) and 1-benzyl-3-(3-phenylpropyl)urea (9, cardiac myosin ATPase activation?=?53.3%; FS?=?30.04; EF?=?18.27) showed significant activity in?vitro and in?vivo. The change of phenyl ring with tetrahydropyran-4-yl moiety viz., 1-(3-phenylpropyl)-3-((tetrahydro-2H-pyran-4-yl)methyl)urea (14, cardiac myosin ATPase activation?=?81.4%; FS?=?20.50; EF?=?13.10), and morpholine moiety viz., 1-(2-morpholinoethyl)-3-(3-phenylpropyl)urea (21, cardiac myosin ATPase activation?=?44.0%; FS?=?24.79; EF?=?15.65), proved to be efficient to activate the cardiac myosin. The potent compounds 1, 9, 14 and 21 were found to be selective for cardiac myosin over skeletal and smooth myosins. Thus, these urea derivatives are potent scaffold to develop as a newer cardiac myosin activator for the treatment of systolic heart failure.

Compounds with cardiac myosin activating function and pharmaceutical composition containing the same for treating or preventing heart failure

The present invention relates to a compound having a cardiotonic activating function and a pharmaceutical composition containing the same. The composition comprising the compound according to the present invention is effective in preventing or treating heart failure. In addition, the compound is represented by chemical formula 2 or is pharmaceutically acceptable salt thereof.COPYRIGHT KIPO 2016

Compounds with cardiac myosin activating function and pharmaceutical composition containing the same for treating or preventing heart failure

Disclosed are a compound having cardiotonic activity and a pharmaceutical composition containing the same, and the composition containing the compound, according to the present invention, is useful for preventing and treating heart failure.COPYRIGHT KIPO 2016